Product Detail  

Semaglutide (CAS: 910463‑68‑2) is a synthetic lipid‑modified peptide analogue, consisting of a 31‑amino‑acid backbone with a covalently attached C18 fatty di‑acid side‑chain via a hydrophilic spacer. It shares 94% amino‑acid sequence homology with native human GLP‑1 peptide. The substance appears as white to almost white hygroscopic powder, with molecular formula C₁₈₇H₂₉₁N₄₅O₅₉ and molecular weight of 4113.58 g/mol. Structural modifications grant it resistance against DPP‑4 enzymatic degradation and enable reversible binding to serum albumin, contributing to its extended in‑vivo half‑life property.

• Basic information

  Semaglutide, also known as semaglutide in Chinese, is a new type of therapeutic belonging to the class of GLP-1 receptor agonists. Its chemical structure is derived from the modification of naturally occurring glucagon-like peptide-1 (GLP-1), which gives it unique pharmacological properties and is significantly different from the mechanism of action of traditional hypoglycemic.

  Indications

  1. Treatment of type 2 diabetes: It is used for blood sugar control in adult patients with type 2 diabetes on the basis of diet control and exercise. Especially for those patients whose blood sugar is still poorly controlled after treatment with metformin and/or sulfonylurea. Semaglutide can stimulate secretion, and this stimulation is glucose concentration-dependent, that is, it enhances secretion when blood sugar rises, effectively reduces high blood sugar levels, and reduces the risk of hypoglycemia when blood sugar is normal; at the same time, it inhibits glucagon secretion, reduces liver glucose output, and can also delay gastric emptying, prolong nutrient absorption time, and further stabilize blood sugar levels.

  2. Reduction of cardiovascular disease risk: It is suitable for adult patients with type 2 diabetes and cardiovascular disease, and can reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke). It may protect the cardiovascular system by improving endothelial function, reducing inflammatory response and directly protecting the heart.

  3. Weight management: It can be used to assist weight management for adults with BMI ≥ 30kg/m² (obesity) or BMI ≥ 27kg/m² (overweight) and at least one weight-related complication (such as hypertension, dyslipidemia, cardiovascular disease, sleep apnea, etc.). Semaglutide acts on the appetite regulation center of the hypothalamus, increases satiety signals, and affects the reward circuit of the limbic system, reducing the desire for high-fat and high-sugar foods, thereby reducing food intake and achieving weight loss.